Table 4. Completed clinical trials of mTOR inhibitors alone or in combination with chemotherapy in OC.

Phase	Treatment	No. of all gynecologic cancer patients	No. of OC patients	Selected toxicities	Efficacy	Reference
II	Temsirolimus (mTOR inhibitor)	54	54	Grade 3-4 gastrointestinal (10%), metabolic (15%), and pulmonary (6%) toxicities	RR = 9%	Behbakht et al.[25]
					6-month PFS rate = 24%
Cohort	Temsirolimus	6	6	All with hyperglycemia and hypertriglyceremia, resulted in treatment discontinuation in 1 patient	PR rate = 20%	Takano et al.[26]
I	Temsirolimus + topotecan	15	7	Grade 3-4 neutropenia and thrombocytopenia	RR = 0	Temkin et al.[28]
					One SD for 6 months
Ib	Temsirolimus + PLD	20	NA	Grade 3-4 fatigue (5%), nausea (16%), mucositis (21%), vomiting (16%), rash (11%), and hand-foot syndrome (21%)	NA	Boers-Sonderen et al.[29]
I	Temsirolimus + carboplatin + paclitaxel	39	6	Grade 3-4 neutropenia (89%), thrombocytopenia (21%), and pulmonary toxicities (5%)	RR = 50% (3/6)	Kollmannsberger et al.[30]
					SD rate = 50% (3/6)
I	Ridaforolimus + carboplatin + paclitaxel	22	9	Grade 3/4 myelotoxicity in 21 of 22 patients	PR rate = 32%	Chon et al.[31]
I	Everolimus + paclitaxel	16	3	Grade 3 neutropenia, anemia, thrombocytopenia, mucositis, and fatigue	NA	Campone et al.[32]
II	Temsorolimus + tranbectedin	17	17 (all clear cell OC)	Not mentioned	RR = 18%	Takano et al.[33]

PLD, pegylated liposomal doxorubicin; RR, response rate; PFS, progression-free survival; PR, partial response; SD, stable disease; NA, not available.